Prediabetes and What It Means: The Epidemiological Evidence

被引:222
作者
Echouffo-Tcheugui, Justin B. [1 ,2 ,3 ,4 ]
Selvin, Elizabeth [3 ,4 ,5 ]
机构
[1] Johns Hopkins Univ, Dept Med, Div Endocrinol Diabet & Metab, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[3] Welch Prevent Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
来源
ANNUAL REVIEW OF PUBLIC HEALTH, VOL 42, 2021 | 2021年 / 42卷
基金
美国国家卫生研究院;
关键词
prediabetes; impaired glucose tolerance; impaired fasting glucose; epidemiology; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; DIABETES PREVENTION PROGRAM; FASTING PLASMA-GLUCOSE; ALL-CAUSE MORTALITY; PROSPECTIVE COHORT ANALYSIS; FOLLOW-UP; ATHEROSCLEROSIS RISK; INSULIN-RESISTANCE; GLYCATED ALBUMIN;
D O I
10.1146/annurev-publhealth-090419-102644
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Prediabetes is an intermediate stage between normal glycemia and diabetes and is highly prevalent, especially in older age groups and obese individuals. Five different definitions of prediabetes are used in current practice, which are based on different cut points of HbA(1C), fasting glucose, and 2-h glucose. A major challenge for the field is a lack of guidance on when one definition might be preferred over another. Risks of major complications in persons with prediabetes, including diabetes, cardiovascular disease, kidney disease, and death, also vary depending on the prediabetes definition used. Randomized clinical trials have demonstrated that lifestyle and pharmacologic interventions can be cost-effective, prevent diabetes, and improve cardiovascular risk factors in adults with prediabetes. However, the practical implementation of lifestyle modification or the use of metformin for treating prediabetes is inadequate and complicated by a lack of agreement on how to define the condition. Establishing consensus definitions for prediabetes should be a priority and will help inform expansion of insurance coverage for lifestyle modification and improve current screening and diagnostic practices.
引用
收藏
页码:59 / 77
页数:19
相关论文
共 115 条
[1]   Evidence and Challenges for Translation and Population Impact of the Diabetes Prevention Program [J].
Ackermann, Ronald T. ;
O'Brien, Matthew J. .
CURRENT DIABETES REPORTS, 2020, 20 (03)
[2]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[3]  
2-S
[4]   Reach and Use of Diabetes Prevention Services in the United States, 2016-2017 [J].
Ali, Mohammed K. ;
Bullard, Kai McKeever ;
Imperatore, Giuseppina ;
Benoit, Stephen R. ;
Rolka, Deborah B. ;
Albright, Ann L. ;
Gregg, Edward W. .
JAMA NETWORK OPEN, 2019, 2 (05)
[5]   Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014 [J].
Ali, Mohammed K. ;
Bullard, Kai McKeever ;
Saydah, Sharon ;
Imperatore, Giuseppina ;
Gregg, Edward W. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05) :392-403
[6]   How Effective Were Lifestyle Interventions In Real-World Settings That Were Modeled On The Diabetes Prevention Program? [J].
Ali, Mohammed K. ;
Echouffo-Tcheugui, Justin B. ;
Williamson, David F. .
HEALTH AFFAIRS, 2012, 31 (01) :67-75
[9]  
[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004]
[10]   The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes Among Women With and Without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow-Up [J].
Aroda, V. R. ;
Christophi, C. A. ;
Edelstein, S. L. ;
Zhang, P. ;
Herman, W. H. ;
Barrett-Connor, E. ;
Delahanty, L. M. ;
Montez, M. G. ;
Ackermann, R. T. ;
Zhuo, X. ;
Knowler, W. C. ;
Ratner, R. E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (04) :1646-1653